Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent must be obtained and documented prior to study-specific screening procedures.
A histologically or cytologically confirmed advanced solid tumor
≥ 18 years of age
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
Karnofsky performance status ≥ 70%
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after participation.
Females of childbearing potential must have a negative serum pregnancy test.
Laboratory results must meet study criteria.
You may not be if
Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first infusion
Surgery within 4 weeks prior to first infusion
Known untreated brain metastases
Pregnant or breastfeeding
Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
Other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
Clareo Health | A Study of ARQ 171 in Patients With Advanced Solid Tumors
